14 Oct | CHICC Expert Workshop: Non-Dilutive Funding – Extending your R&D Runway
This CHICC Expert Workshop will unpack the non-dilutive funding options available to health technology innovators, including grants, R&D tax incentives and R&D capital. Gain practical insights to help you identify the right opportunities, strengthen your funding strategy and keep your innovation moving forward.
Date: Wednesday 14 October 2026
Time: 10:00am – 12:45pm (including morning break)
Venue: ACMD Building, The Discovery Studio, Level 7, 27 Victoria Parade, Fitzroy, VIC 3065
Session format: In-person only with presentations, practical advice and interactive Q&A
Registration*: Free to attend, but registration essential
*Registrations close 9:00am Tuesday 13 October 2026
Who should attend?
- Healthtech innovators (including medtech, digital and connected health), founders and CXOs
- CFOs, commercial leads & business strategists
- Medtech, digital and connected health professionals.
This CHICC workshop is powered by ANDHealth and supported by the Victorian Government.
In the competitive world of innovation, securing funding can be the key to success. This expert workshop will provide an in-depth analysis of non-dilutive funding mechanisms available to your digital health business, including the R&D tax incentives (RDTI) and government grant strategies.
Join R&D tax partner Kate Mahady (FB Rice), non-dilutive funding strategist Stuart Haines (Haines Consulting Group) and fund program leader Alex Barty (ANDHealth) as they discuss how to effectively navigate the Australian grants and tax incentives landscape, simplifying the process and identifying the right financial support to fuel your business innovation and growth.
We will also unpack the potential knock-on effects of the proposed future changes in this year's Federal Budget and outline how Australian innovators can effectively compete for the capital that remains available.
Don’t miss this crucial session, designed to help you move beyond asking “what grants are available?” and instead build a smarter funding strategy to de-risk your business.
What we’ll cover:
- Positioning RDTI as your #1 strategic capital lever – not just a year-end compliance exercise
- Proposed changes to the RDTI program for the 2029 financial year and how this might affect your R&D funding
- How to effectively substantiate an RDTI claim, prepare for a stronger submission and avoid compliance pitfalls
- Alternative funding pathways, including MRFF; CRC-P; state-based programs; and industry collaborations
- Aligning grant applications to technical, clinical and commercial milestones to de-risk your path to market
- What makes a grant application compelling – and why others fall short.
.svg)